Search Results - Attal, Hila

  • Showing 1 - 5 results of 5
Refine Results
  1. 1
    Intracellular cross-talk between the GPCR CXCR1 and CXCR2: Role of carboxyl terminus phosphorylation sites

    Intracellular cross-talk between the GPCR CXCR1 and CXCR2: Role of carboxyl terminus phosphorylation sites by Attal, Hila, Cohen-Hillel, Efrat, Meshel, Tsipi, Wang, Ji Ming, Gong, Wanghua, Ben-Baruch, Adit

    Get full text
    Items that this one cites
    Items that cite this one
    Article
    Save to List
    Saved in:
  2. 2
    A new polycythaemia vera‐associated SOCS3 SH2 mutant (SOCS3F136L) cannot regulate erythropoietin responses

    A new polycythaemia vera‐associated SOCS3 SH2 mutant (SOCS3F136L) cannot regulate erythropoietin responses by Suessmuth, Yvonne, Elliott, Joanne, Percy, Melanie J., Inami, Mitsuharu, Attal, Hila, Harrison, Claire N., Inokuchi, Koiti, McMullin, Mary‐Frances, Johnston, James A.

    Get full text
    Items that this one cites
    Items that cite this one
    Article
    Save to List
    Saved in:
  3. 3
    CXCL8-induced FAK phosphorylation via CXCR1 and CXCR2: Cytoskeleton- and integrin-related mechanisms converge with FAK regulatory pathways in a receptor-specific manner

    CXCL8-induced FAK phosphorylation via CXCR1 and CXCR2: Cytoskeleton- and integrin-related mechanisms converge with FAK regulatory pathways in a receptor-specific manner by Cohen-Hillel, Efrat, Yron, Ilana, Meshel, Tsipi, Soria, Gali, Attal, Hila, Ben-Baruch, Adit

    Get full text
    Items that cite this one
    Article
    Save to List
    Saved in:
  4. 4
    Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial

    Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial by Mateos, Maria-Victoria, Blacklock, Hilary, Schjesvold, Fredrik Hellem, Oriol, Albert, Simpson, David, George, Anupkumar, Goldschmidt, Hartmut, Larocca, Alessandra, Chanan-Khan, Asher, Sherbenou, Daniel, Avivi, Irit, Benyamini, Noam, Iida, Shinsuke, Matsumoto, Morio, Suzuki, Kenshi, Ribrag, Vincent, Usmani, Saad Z, Jagannath, Sundar, Ocio, Enrique M, Rodriguez-Otero, Paula, San Miguel, Jesus, Kher, Uma, Farooqui, Mohammed, Liao, Jason, Marinello, Patricia, Lonial, Sagar

    Request full text
    Items that cite this one
    Article
    Save to List
    Saved in:
  5. 5
    Pembrolizumab plus lenalidomide and dexamethasone for patients with treatment-naive multiple myeloma (KEYNOTE-185): a randomised, open-label, phase 3 trial

    Pembrolizumab plus lenalidomide and dexamethasone for patients with treatment-naive multiple myeloma (KEYNOTE-185): a randomised, open-label, phase 3 trial by Usmani, Saad Zafar, Schjesvold, Fredrik Hellem, Oriol, Albert, Karlin, Lionel, Cavo, Michele, Rifkin, Robert M, Yimer, Habte Aragaw, LeBlanc, Richard, Takezako, Naoki, McCroskey, Robert Donald, Lim, Andrew Boon Ming, Suzuki, Kenshi, Kosugi, Hiroshi, Grigoriadis, George, Avivi, Irit, Facon, Thierry, Jagannath, Sundar, Lonial, Sagar, Ghori, Razi Uddin, Farooqui, Mohammed Z.H, Marinello, Patricia, San-Miguel, Jesús

    Request full text
    Items that cite this one
    Article
    Save to List
    Saved in:

Search Tools: